Pre-Test Evolving Perspectives on Depression: Chronic vs. Episodic Treatment in MDD and the Role of the GABA System Pre-Test In addition to low response/remission rates, which of the following factors commonly associated with a lack of adherence to long-term/chronic antidepressant pharmacotherapy may be best addressed by emerging innovative therapies designed to increase glutamate and GABA neurotransmitter function? Acute and chronic side effects Complexity of treatment regimen Delayed onset of action Fears of addiction Unsure Deficits of GABA, combined with evidence that fluctuations of neuroactive steroids contribute to depression, have led to development of GABAergic agents, including formulations of allopregnanolone, which employ which of the following mechanisms? Enhancement of excitatory effects of GABAergic neurons Downregulation of allopregnanolone Positive allosteric modulation of GABAergic neurotransmission Reduced expression of GABA synthesizing enzymes Unsure Which of the following, taken orally for 14 days, has demonstrated statistically significant differences in change from baseline in HAMD-17 total scores at Day 15 in numerous studies of women with PPD, and of women and men with MDD? Brexanolone Ganaxolone Nandrolone Zuranolone Unsure How confident are you in your ability to describe the evolving understanding of the neurobiological pathophysiology of MDD and its potential implications for patient care? Very confident Confident Somewhat confident Not very confident Not at all confident
